Compare iShares MSCI South Africa ETF (EZA) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI South Africa ETF vs Medpace Holdings Inc — how do they compare? iShares MSCI South Africa ETF trades at $68.53, while Medpace Holdings Inc trades at $597.39 (market cap $16.90B). The key difference: Medpace Holdings Inc is trading nearer its 52-week high, iShares MSCI South Africa ETF nearer its low. Which is the better fit depends on your goals.
| EZA | MEDP | |
|---|---|---|
Sector | Broad Market / Factor | Technology |
52-Week High | $81.60 | $620.59 |
52-Week Low | $56.57 | $393.42 |
Market Cap | — | $16.90B |
Enterprise Value | — | $16.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EZA trades at $68.33, down 2.01% today, with a bullish technical bias from moving averages but bearish oscillators. Key support is at $68 and resistance at $70. The company has a dividend scheduled for June 2026, but financial ratios like P/E and P/S are not provided in the data.
Outlook is mixed: technical strength contrasts with macroeconomic headwinds highlighted in recent news. Risks include exposure to South African sectors sensitive to interest rates and commodities. Investment appeal hinges on navigating these challenges amid a bullish trend signal.
MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.
MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI South Africa ETF
EZA is a country-specific ETF that tracks the South African equity market. It provides exposure to large and mid-cap companies across key sectors like materials and financials, with top holdings such as AngloGold Ashanti and Naspers.
Read more on EZA →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
